A review of national guidelines for management of COPD in Europe
about
Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.COPD heterogeneity: implications for management.Determinants for changing the treatment of COPD: a regression analysis from a clinical audit.Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian settingOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention.Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study.Ischemic ECG abnormalities are associated with an increased risk for death among subjects with COPD, also among those without known heart disease.The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.Phenotyping Before Starting Treatment in COPD?Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Current and new challenges in occupational lung diseases.A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease.Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study.Russian guidelines for the management of COPD: algorithm of pharmacologic treatment.Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease.Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?Pharmacological treatment for COPD; GOLD 2017 changes direction.Patterns and management of chronic obstructive pulmonary disease in urban and rural China: a community-based survey of 25 000 adults across 10 regions.Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same?Community pharmacists’ knowledge of COPD, and practices and perceptions of medication counseling of COPD patients.Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary careWhat have we learned from observational studies and clinical trials of mild to moderate COPD?
P2860
Q30365242-76A824C3-B53A-47F4-9920-7ACB00E4C5D6Q33768773-338948F6-BE40-49BB-8400-3921C5BD8102Q33854276-D383730F-7CDA-414B-BF2F-B3DFA9796D8DQ36356295-7906D56A-53C2-434C-8158-E6D9F1F2BC0BQ36694767-172826FB-12B6-4CC9-B2D4-EEEBC4E1796CQ36981197-63F2C59E-B6A9-4992-8516-B80462E2EC35Q37407443-C52891DC-6A38-4453-B7A4-D5E6AF96C122Q37583834-A4CE58B0-A45B-488C-9862-6E659C0547FCQ37613913-F0D23080-756C-49E5-92BF-5FD51FA30414Q38598984-3E10EAD1-380A-4421-B521-8195D1B19BA7Q38598993-C4404B04-E379-4020-8BB6-E80335A9B5FEQ38655574-4FCC2371-B205-4A78-8305-10617F7F0ED2Q38819989-20A7F8B4-872A-47DB-B344-10404BBE5851Q39226768-FDA6EA9B-5487-4909-ACC2-9BF1DD322814Q40598255-CCA90CAB-E5C3-4AF3-BADA-436D09721030Q46591119-712E9646-3887-4779-8408-6D2D15A3AF11Q47138049-085A2D0E-79A3-4182-A771-EBE843361C4AQ47147233-B34989F7-744A-4037-93DA-A382A609DFC9Q47553955-7AF4FD83-2B56-4E07-AD6D-8727335CA320Q47653653-6AD71E8E-EEC9-45D8-8581-A31E1D25D8E9Q47661714-8CCC0A09-0F53-4512-842A-F8F8FB8BBA2DQ47718704-FD772B5B-0007-4760-95F1-129A8A1698F5Q47788593-F3FAA55F-E37B-4F2B-9B8D-A488C447C925Q48343193-2D97414C-8384-4BF0-B1A1-ECFA36DCDAEFQ54336237-7E803E71-15C0-4186-BA48-C394036A9E89Q55318974-3A170BA3-034E-4B3B-8BE9-EBAB41EA9E94Q55335157-1A9597F8-B349-4580-8D63-991CA301C0CFQ55432750-5ABB0102-8534-4E47-AC9B-051020A091E2Q55650005-B949B83F-D2E2-4DB5-BFBB-7A1BCC16BFA6Q57777292-03812D1B-E9B5-4A90-A98C-A3996DC5C678Q57777296-2830B0CB-D89B-45B9-858E-E6E056125A4A
P2860
A review of national guidelines for management of COPD in Europe
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A review of national guidelines for management of COPD in Europe
@ast
A review of national guidelines for management of COPD in Europe
@en
A review of national guidelines for management of COPD in Europe
@nl
type
label
A review of national guidelines for management of COPD in Europe
@ast
A review of national guidelines for management of COPD in Europe
@en
A review of national guidelines for management of COPD in Europe
@nl
prefLabel
A review of national guidelines for management of COPD in Europe
@ast
A review of national guidelines for management of COPD in Europe
@en
A review of national guidelines for management of COPD in Europe
@nl
P2093
P2860
P50
P3181
P1476
A review of national guidelines for management of COPD in Europe
@en
P2093
Alexander G. Chuchalin
David Halpin
Hannu Kankaanranta
Jaromir Zatloukal
João Cardoso
Paweł Śliwiński
Thomas Sandström
P2860
P304
P3181
P356
10.1183/13993003.01170-2015
P407
P577
2016-02-01T00:00:00Z